VDT PACE 样方案治疗复发/难治性多发性骨髓瘤的疗效
该研究在本中心对2006至2017年间141例复发/难治性多发性骨髓瘤患者接受VDT PACE样方案(VPLRs)进行意向性治疗分析,中位年龄59.7岁,66.7%为男性,中位既往治疗4线,66.7%曾接受干细胞移植。≥微小缓解率68.4%,≥部分缓解率54.4%,≥非常好的部分缓解率10.3%,中位无进展生存期3.1个月(95%CI 1.9-3.9),中位总生存期8.1个月(95%CI 6.2-9.9)。年龄≥60岁(HR 2.3,95%CI 1.4-3.7,P=0.0008)和R-ISS III期(HR 2.4,95%CI 1.3-4.0,P=0.003)预测更短的总生存期。
要点
- VPLRs在重度预处理复发/难治性多发性骨髓瘤中有效,≥微小缓解率68.4%,≥部分缓解率54.4%。
- 中位无进展生存期3.1个月(95%CI 1.9-3.9),中位总生存期8.1个月(95%CI 6.2-9.9)。
- VPLR后接受干细胞移植者中位总生存期15.1个月(95%CI 10.3-20.8)。
核心结论
- VPLRs在重度预处理的复发/难治性多发性骨髓瘤患者中有效。
- 适合的患者中,干细胞移植可用于巩固VPLR的疗效。
研究设计与样本
- 在本中心对2006年至2017年间141例接受VPLRs的复发/难治性多发性骨髓瘤患者进行意向性治疗分析。
- 中位年龄59.7岁,66.7%为男性,52.4%具有高危细胞遗传学。
- 患者接受中位4线(范围1-14)既往治疗,66.7%曾接受干细胞移植。
- 95例(67.4%)接受VDT PACE,20例(14.2%)接受VD PACE,26例(18.4%)接受其他VPLRs;中位1周期(范围1-9)。
主要发现
- ≥微小缓解率68.4%,≥部分缓解率54.4%,≥非常好的部分缓解率10.3%。
- 中位无进展生存期3.1个月(95%CI 1.9-3.9),中位总生存期8.1个月(95%CI 6.2-9.9)。
- 116例(82.3%)在VPLR后接受后续治疗,其中71例(61.2%)接受全身化疗,45例(38.8%)接受干细胞移植。
- VPLR后接受干细胞移植者的中位总生存期为15.1个月(95%CI 10.3-20.8)。
- 年龄≥60岁(HR 2.3,95%CI 1.4-3.7,P=0.0008)和R-ISS III期(HR 2.4,95%CI 1.3-4.0,P=0.003)预测接受VPLR患者更短的总生存期。
临床怎么用
- 作者认为VPLRs在重度预处理的复发/难治性多发性骨髓瘤中有效。
- 作者认为适合的患者中,干细胞移植可用于巩固VPLR的疗效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Experience with intensive chemotherapy for relapsed/refractory multiple myeloma (RRMM) using VDT PACE regimen and its modifications (VDT PACE-like regimens: VPLRs) outside TOTAL THERAPY trials is limited. We analyzed the outcomes of 141 patients with RRMM who received VPLRs at our center between 2006 and 2017 in an intent-to-treat analysis. Median age was 59.7 years and 66.7% of patients were male. A median of 2.2 years (range 0.02-11.4) separated diagnosis of myeloma and inititation of VPLR. High-risk cytogenetics were present in 52.4% patients. Patients received a median of 4 (range 1-14) prior therapies, including stem cell transplant (SCT) in 66.7% patients. Ninety-five (67.4%) patients received VDT PACE, 20 (14.2%) patients received VD PACE and 26 (18.4%) patients received other VPLRs. Patients received a median of 1 cycle (range 1-9) of VPLR. We observed ≥ minimal response in 68.4%, ≥ partial response (PR) in 54.4% and ≥ very good PR in 10.3% patients. Median progression-free survival was 3.1 months (95% CI, 1.9-3.9) and median overall survival (OS) was 8.1 months (CI, 6.2-9.9). One-hundred and sixteen (82.3%) patients received some therapy after VPLR; 71 (61.2%) received systemic chemotherapy, while 45 (38.8%) underwent SCT. Median OS for those who received SCT after VPLR was 15.1 months (CI, 10.3-20.8). Age ≥ 60 years (hazard ratio [HR] 2.3 [CI, 1.4-3.7]; P = 0.0008) and R-ISS III stage (HR- 2.4 [CI, 1.3-4.0]; P = 0.003) predicted shorter OS in patients receiving VPLR. VPLRs are effective in heavily pre-treated RRMM. In fit patients, SCT can be used to consolidate the response to VPLR.
引用
- Lakshman A, Singh PP, Rajkumar SV, et al. Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. Am J Hematol. 2017. PMID: 29067723. doi:10.1002/ajh.24954
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。